Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials

Table 1

Baseline characteristics and Jadad scores of the included studies.

Study, year	Type of stents	Sample size		Age (y)		Male %		Hypertension, %		Diabetes, %		Previous MI		Previous CABG		Dyslipidemia		Smoking		Follow-up
		DCB	EES	DCB	EES	DCB	EES	DCB	EES	DCB	EES	DCB	EES	DCB	EES	DCB	EES	DCB	EES	ACG, m	Clinical, y
DARE, 2018 [5]	DES and BMS	141	137	66 ± 11	65 ± 10	72%	84%	64%	67%	31%	33%	53%	52%	14%	16%	59%	60%	17%	13%	6	1
Restore, 2018 [4]	DES	86	86	67 ± 10	66 ± 9	70.9%	72.1%	69.8%	75.6%	50.0%	44.2%	30.2%	25.6%	NR	NR	NR	NR	46.5%	43.0%	9	1
RIBS IV, 2015 [9, 12]	DES	154	155	66 ± 10	66 ± 10	82.5%	83.9%	71%	78%	49%	43%	60%	60%	4%	7%	73%	66%	59%	75%^∗	6–9	1
RIBS V, 2014 [11, 14]	BMS	95	94	67 ± 11	64 ± 12	86.3%	87.2%	72%	72%	32%	20%	47%	50%	10%	11%	71%	78%	58%	56%	6–9	1
SEDUCE, 2014 [10]	BMS	25	25	67.6 ± 7.7	64.2 ± 11	72%	100%	64%	60%	24%	4%	48%	40%	NR	NR	96%	96%	21%	12%	9	1
TIS, 2016 [6, 12]	BMS	68	68	65.6 ± 11	65.5 ± 11	63.2%	67.7%	NR	NR	25.0%	26.5%	63.2%	60.3%	4.4%	8.8%	NR	NR	45.6%	42.7%	12	1

Data are shown as percentage or mean ± standard deviation, unless otherwise stated. DCB, drug-coated balloons; EES, everolimus-eluting stents; DES, drug-eluting stents; BMS, bare-mental stents; MI, myocardial infarction; CABG, coronary artery bypass grafting; NR, not reported; ACG, angiography.